MaxCyte, Inc. (MXCT.L)
| Previous close | 313.00 |
| Open | 316.00 |
| Bid | 310.00 x 0 |
| Ask | 316.00 x 0 |
| Day's range | 312.00 - 316.00 |
| 52-week range | 180.00 - 430.00 |
| Volume | |
| Avg. volume | 27,342 |
| Market cap | 326.759M |
| Beta (5Y monthly) | 1.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.30 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.65 |
Simply Wall St.We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
GlobeNewswireMaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
ROCKVILLE, Md., April 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the first quarter 2024 after the U.S. market close on Tuesday, May 7th, 2024. Company management will host a conference cal
- GlobeNewswire
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programsROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications and Be Biopharma (“Be Bio”), a company pioneer
